[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Goto T, Takano M, Hirata J, Kohno T, Ohtsuka S, Fujiwara K, Tsuda H: p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer. Int J Cancer; 2009 Jul 15;125(2):339-44
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer.
  • The aim of this study is to investigate p16INK4a expression by immunocytochemistry for ascites in advanced ovarian cancer and explore the possibility to predict chemotherapeutic response and prognosis.
  • The immunocytochemical study was performed on cytology of ascites obtained from 37 Stage III or Stage IV ovarian cancer patients with measurable disease before platinum/taxane-based first-line chemotherapy following primary cytoreductive surgery or as neoadjuvant chemotherapy.
  • In vitro expression of p16INK4a protein was also examined for both parent chemosensitive and acquired chemoresistant ovarian cancer cell lines.
  • Our data suggest that p16INK4a expression in cytology of ascites is a candidate marker in prediction of the primary response to chemotherapy and prognosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ascites / pathology. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 UICC.
  • (PMID = 19330839.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


2. Recchia F, De Filippis S, Rosselli M, Saggio G, Carta G, Rea S: Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. Eur J Gynaecol Oncol; 2001;22(4):287-91
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study.
  • BACKGROUND AND RATIONALE: Non-curative surgical cytoreduction of advanced tumors is associated with increased proliferation of the remaining tumor cells.
  • Thus, appropriate preoperative chemotherapy should prevent both cell proliferation and the increase of resistant cells.
  • The aim of the present study was to evaluate the efficacy and toxicity of primary chemotherapy (P-CT) in previously untreated patients with stage IV ovarian cancer (OC).
  • PATIENTS AND METHODS: Thirty-four patients with stage IV OC were treated from January 1993 to April 2000 with P-CT.
  • Eligibility criteria included: histologically or cytologically confirmed, unresectable stage IV OC and performance status < or = 3.
  • After the operation patients received two further courses of chemotherapy that were tailored according to their individual response.
  • Median time to progression was 16.45 months (range 4.8-90.4+), median survival time was 28 months (range 4.5 - 90.4+): 1-year survival rate was 94%.
  • CONCLUSION: Neoadjuvant treatment with CBDCA with either CTX and EPI or Taxol is feasible and shows activity in OC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cystadenocarcinoma / drug therapy. Cystadenocarcinoma / mortality. Cystadenocarcinoma / pathology. Disease Progression. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11695811.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


3. Kawaguchi R, Furukawa N, Morimoto Y, Ohi M, Osawa T, Koike H, Miyake T: [A case of ovarian cancer stage IV and advanced rectal cancer responding to paclitaxel/carboplatin]. Gan To Kagaku Ryoho; 2004 Apr;31(4):619-22
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of ovarian cancer stage IV and advanced rectal cancer responding to paclitaxel/carboplatin].
  • A 43-year-old woman who had ovarian cancer with massive ascites and pleural effusion as well as rectal cancer underwent probe laparotomy.
  • Three courses of chemotherapy with paclitaxel and carboplatin (T-J therapy) were carried out.
  • Following chemotherapy, the ascites and pleural effusion had completely disappeared and the size of rectal cancer had shrunk as well.
  • The chemotherapeutic effect was evaluated as a partial response in the rectal cancer.
  • Three further courses of chemotherapy were performed.
  • There is no evidence of recurrence of ovarian cancer and rectal cancer 3 years after the first surgery.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Serous / drug therapy. Neoplasms, Multiple Primary / drug therapy. Ovarian Neoplasms / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Hysterectomy. Lymph Node Excision. Neoplasm Staging. Omentum / surgery. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114712.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. Watanabe M, Aoki Y, Kurata H, Tanaka K: Pneumocystis carinii pneumonia in a patient with stage IV ovarian cancer. Gynecol Oncol; 2002 Nov;87(2):225-7
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pneumocystis carinii pneumonia in a patient with stage IV ovarian cancer.
  • CASE: A 42-year-old female with stage IV ovarian cancer developed P. carinii pneumonia during radiotherapy for brain metastasis while receiving 7 weeks of prednisolone.
  • Four weeks before the diagnosis, her lymphocyte count dropped to 350/microl.
  • However, she was not able to receive any additional therapy for her ovarian cancer.
  • CONCLUSION: Cancer patients who receive corticosteroids during chemotherapy or radiation therapy are at risk of developing P. carinii pneumonia and should receive P. carinii pneumonia prophylaxis.
  • [MeSH-major] Ovarian Neoplasms / microbiology. Pneumonia, Pneumocystis / etiology
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Staging. Prednisolone / adverse effects. Prednisolone / therapeutic use. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12477458.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


5. Yokoyama Y, Futagami M, Fukushi Y, Sakamoto T, Higuchi T, Fujii S, Sato S, Takami H, Saito Y: Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer. Arch Gynecol Obstet; 2000 Apr;263(4):206-7
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer.
  • Although chemotherapy is indispensable for the treatment of ovarian cancer, secondary acute leukemia has become increasingly important as one of the most unfavorable late effects according to widespread long-term chemotherapy.
  • We report a patient suffering from acute nonlymphocytic leukemia (ANLL) 3 years after treatment for stage IV ovarian cancer began.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cystadenocarcinoma, Mucinous / drug therapy. Leukemia, Myeloid, Acute / chemically induced. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Biopsy. Bone Marrow / pathology. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Idarubicin / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Middle Aged. Mitoxantrone / therapeutic use. Prednisolone / therapeutic use. Remission Induction / methods. Reoperation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10834334.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 04079A1RDZ / Cytarabine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; Q20Q21Q62J / Cisplatin; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


6. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF: Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary. Gynecol Oncol; 2002 Jun;85(3):459-63
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary.
  • OBJECTIVE: Malignant mixed müllerian tumor (MMMT) of the ovary is a rare tumor with a dismal prognosis.
  • The most effective therapy is unknown.
  • The current study was undertaken to characterize a group of patients treated as if they had aggressive epithelial ovarian tumors, with cytoreductive surgery and combination paclitaxel/platinum chemotherapy.
  • METHODS: Retrospective analysis of data obtained from tumor registry and hospital records of cases of malignant mixed müllerian tumor between January 1, 1992 and January 1, 2000 treated at the Massachusetts General Hospital, Brigham and Women's Hospital, and University of Vermont was performed.
  • Only patients treated with combination paclitaxel and platinum therapy were included in the analysis.
  • Data were collected regarding cytoreduction, response to chemotherapy, disease-free interval, and survival.
  • Twenty-eight patients with a clearly ovarian primary had received treatment with combination paclitaxel and platinum.
  • Paclitaxel and carboplatin was given as second-line therapy in 2 patients who had chemoresponsive but incurable disease; the remaining patients were treated with paclitaxel and platinum therapy as first-line therapy.
  • These 28 patients had a median (range) age of 66 (46-84 years) and stage was I in 2 patients, II in 3, III in 18, and IV in 5.
  • Treatment was generally well tolerated.
  • Sixteen patients of 26 treated with paclitaxel and platinum as first-line therapy achieved a complete clinical response (55%) and 6 patients achieved partial response for a total response rate of 72%.
  • Optimal cytoreduction was associated with increased time to recurrence (P = 0.001) but not with survival.
  • CONCLUSION: Although treatment fails many patients, a minority of patients with MMMT in this highly selected population do unexpectedly well.
  • An aggressive approach with surgery and combination paclitaxel-platinum chemotherapy appears to offer very effective therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mixed Tumor, Mullerian / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12051874.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Mok JE, Kim YM, Jung MH, Kim KR, Kim DY, Kim JH, Kim YT, Nam JH: Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):101-5
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy.
  • This study reviews the clinical outcome and prognosis of patients with malignant mixed müllerian tumors (MMMTs) of the ovary treated with optimal cytoreductive surgery, leaving no residual disease, and platinum-based chemotherapy.
  • Ten patients diagnosed with MMMT of the ovary after complete surgical staging from February 1993 to February 2004 at Asan Medical Center in Korea were studied retrospectively.
  • Seven patients received ifosfamide/cisplatin chemotherapy, and the remaining three patients received other platinum-based combination chemotherapy.
  • Demographic data, pathologic findings, treatments, and survival time were reviewed.
  • Of the ten patients, two were scored at FIGO stage IIC, seven were at stage IIIC, and one was at stage IV.
  • The median survival time of all ten patients was 46 months.
  • Platinum-based combination chemotherapy after optimal cytoreductive surgery may be effective in the treatment of ovarian MMMT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Mixed Tumor, Mullerian / drug therapy. Mixed Tumor, Mullerian / mortality. Ovarian Neoplasms / mortality. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Probability. Retrospective Studies. Risk Assessment. Sampling Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445618.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


8. Zhang J, Chen AP, Wang B, Zhao SP, Liu LZ, Dai SZ: [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer]. Ai Zheng; 2008 Dec;27(12):1331-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer].
  • BACKGROUND & OBJECTIVE: Abnormal expression and activation of epidermal growth factor receptor (EGFR), which is closely related to the recurrence and poor prognosis of ovarian cancer, can promote chemotherapy resistance of tumor cells.
  • Lung resistance protein (LRP), a multidrug resistance protein causing platinum-resistance, is an independent factor in predicting chemotherapy sensitivity to ovarian cancer.
  • This study was to explore the correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer.
  • METHODS: Expressions of EGFR and LRP in 76 specimens of ovarian malignant tumor, nine borderline tumor, 17 benign tumor and 15 normal ovary were studied using immunohistochemistry.
  • Patients with ovarian cancer were followed up.
  • Correlations of EGFR and LRP to chemotherapy efficacy and survival time of patients with ovarian cancer after operation were analyzed.
  • RESULTS: The positive rates of EGFR and LRP in malignant specimens (73.68% and 71.79%) were significantly higher than those in normal and benign ones (P <0.01).
  • EGFR was highly expressed in ovarian cancer patients at late stage (III-IV), with poor differentiation and ascites (P <0.05).
  • The short-term efficacy rates of ovarian cancer were lower in patients with positive expressions of EGFR and LRP (57.14% and 53.70%) than in those with negative expressions (P<0.05).
  • The positive rates of EGFR and LRP were significant higher in patients with chemotherapy resistance (92.86% and 85.71%) than in those sensitive to chemotherapy (P<0.05).
  • The three-year survival rate of ovarian cancer patients was 53.00%.
  • Patients with positive EGFR and LRP and poor short-term efficacy after chemotherapy had short survival time (P<0.01).
  • CONCLUSION: The expression of EGFR and LRP could be used to predict chemotherapy resistance and prognosis of ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Drug Resistance, Neoplasm. Ovarian Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cisplatin / pharmacology. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Mucinous / drug therapy. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080004.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Ikeba K, Okubo M, Takeda S, Kinoshita K, Maeda H: Five-year results of cyclic semi-high dose neoadjuvant chemotherapy supported by autologous peripheral blood stem-cell transplantation in patients with advanced ovarian cancer. Int J Clin Oncol; 2004 Apr;9(2):113-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year results of cyclic semi-high dose neoadjuvant chemotherapy supported by autologous peripheral blood stem-cell transplantation in patients with advanced ovarian cancer.
  • BACKGROUND: To achieve anti-ovarian tumor responses similar to those obtained with high-dose chemotherapy but with milder side effects, we developed a treatment protocol in which semi-high dose multi-cycle neoadjuvant chemotherapy was supported by autologous peripheral blood stem-cell transplantation (auto-PBSCT).
  • METHODS: Seventeen patients with advanced ovarian cancer were enrolled in this study.
  • Two cycles of semi-high dose neoadjuvant chemotherapy, using carboplatin (AUC, 8.75; average dose, 621 mg/m(2)) and etoposide (average dose, 960 mg/m(2)) were supported by auto-PBSCT and followed by cytoreductive surgery and further chemotherapy.
  • RESULTS: This treatment schedule achieved an overall response rate of 70.6% in 17 patients with stage III or stage IV ovarian cancer.
  • The 5-year disease-free survival rate was 52.9% (95% confidence interval, 29.2%-76.6%) and the median survival time was 63 months (95% confidence interval, 16-79 months).
  • Thus, we obtained superior treatment outcomes in these 17 patients in comparison with published conventional protocols.
  • CONCLUSION: Cyclic semi-high dose neoadjuvant chemotherapy supported by auto-PBSCT may be tolerable and favorable for patients with advanced ovarian cancer.
  • To achieve anti-ovarian tumor responses similar to those obtained with high-dose chemotherapy but with milder side effects, we developed a treatment protocol in which semi-high dose multi-cycle neoadjuvant chemotherapy was supported by autologous peripheral blood stem-cell transplantation (auto-PBSCT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Carboplatin / administration & dosage. Chemotherapy, Adjuvant / methods. Etoposide / administration & dosage. Feasibility Studies. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Staging. Pilot Projects. Survival Analysis. Transplantation, Autologous / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15108043.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


10. Takami M, Idei T, Nakayama Y, Ohta H, Fukai H, Matsumoto H, Togo Y, Sakamoto H, Yamamoto T, Satoh K: [A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP]. Gan To Kagaku Ryoho; 2002 Feb;29(2):305-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP].
  • Carcinosarcoma of the ovary is a very rare and highly malignant neoplasm that accounts for less than 1% of ovarian neoplasms.
  • Survival of patients with advanced stage cancer is poor and the best treatment is not clear.
  • We report the case of a 60-year-old woman who had Stage IV advanced heterogeneous ovarian carcinosarcoma with lung and liver metastases.
  • The lesions were considered surgically incurable, so she was placed on neoadjuvant chemotherapy of combination CPT-11 (60 mg/m2, day 1, 15) and CDDP (60 mg/m2, day 1).
  • Tumor markers of CA125 and LDH decreased remarkably to the normal level after 3 and 4 courses of chemotherapy, respectively.
  • After 7 courses of chemotherapy, the ovarian tumor was obviously reduced, and the lung and liver metastases had disappeared.
  • The current case suggests that combination CPT-11 and CDDP is effective against advanced ovarian carcinosarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinosarcoma / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Hysterotomy. Lymph Node Excision. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11865639.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


11. Rafii A, Deval B, Geay JF, Chopin N, Paoletti X, Paraiso D, Pujade-Lauraine E: Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):777-83
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study.
  • The objective of the study is to determine whether surgery influences the outcome of stage IV ovarian cancer.
  • The study design is as follows: From May 1995 to December 2000, 129 patients with FIGO stage IV ovarian cancer, recruited in 42 centers, were prospectively included in GINECO first-line randomized studies of platinum-based regimens with paclitaxel administered simultaneously or sequentially.
  • Standard peritoneal cytoreductive surgery was defined as a procedure including at least total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and peritoneal debulking.
  • Twenty-two of these 47 patients without initial standard surgery underwent a second surgical procedure, and 17 of the 22 patients completed standard surgery.
  • The median overall survival time in the entire population was 24.3 months (95% confidence interval [CI], 19.5-29.1 months).
  • Patients treated without a cytoreductive surgical procedure had significantly worse median survival (15.1 months; 95% CI, 5.4-24.9 months) than patients who had optimal primary surgery (22.9 months; 95% CI, 15.6-30.1 months), nonoptimal primary surgery (27.1 months; 95% CI, 21.2-32.9 months), or neoadjuvant chemotherapy followed by surgery (45.5 months; 95% CI, 23.5-67.5 months) (P= .001).
  • In conclusion, this study shows a significant benefit of debulking surgery in stage IV ovarian cancer patients who responded to neoadjuvant chemotherapy.
  • Neoadjuvant chemotherapy can help to select patients for surgery.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Epithelial Cells / pathology. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367318.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Aletti GD, Dowdy SC, Podratz KC, Cliby WA: Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol; 2007 Apr;105(1):84-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system.
  • OBJECTIVES: Determine impact of tumor distribution and surgery on prognosis in patients with stage IV epithelial ovarian cancer (EOC).
  • METHODS: Retrospective analysis of stage IV EOC patients undergoing primary surgery between 1994 and 1998.
  • It appears justified in these patients to first exclude those with unresectable pleural disease and then perform laparoscopic assessment to determine extent of disease to triage patients to alternative strategies such as neoadjuvant chemotherapy.
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Triage / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Paclitaxel / administration & dosage. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157903.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Chen CH, Huang CY, Chow SN: Early-stage ovarian carcinoma combined with pulmonary tuberculosis mimicking advanced ovarian cancer: a case report. Int J Gynecol Cancer; 2004 Sep-Oct;14(5):1007-11
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage ovarian carcinoma combined with pulmonary tuberculosis mimicking advanced ovarian cancer: a case report.
  • In patients of ovarian cancer combined with multiple pulmonary nodules, the diagnosis of metastatic ovarian cancer is always considered.
  • An 80-year-old female presented with a rapidly growing ovarian mass, elevated serum CA-125, and multiple pulmonary varying-sized nodular lesions.
  • The pretreatment workup of her lung lesions failed to show a malignant cell, and it also failed to show any evidence of tuberculosis or other infectious diseases.
  • After surgery, her disease was allotted to 'stage IV' epithelial ovarian cancer and adjuvant cytotoxic chemotherapy was then used.
  • For fear of reactivation of pulmonary tuberculosis, the anticancer cytotoxic chemotherapy was postponed and the antituberculous treatment was given instead.
  • After 6-month course of antituberculous therapy, no active lung lesion was detectable.
  • In conclusion, infectious or inflammatory conditions can mimic metastatic disease and therefore add to the difficulty of stage determination.
  • We recommend that there must be positive cytologic or pathologic results of lung lesions to allot a case of ovarian cancer to stage IV.
  • Furthermore, whenever pulmonary lesions are seen on imaging, the possibility of diagnoses other than metastatic ovarian cancer should always be considered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / secondary. Neoplasm Staging. Ovarian Neoplasms / complications. Ovarian Neoplasms / pathology. Tuberculosis, Pulmonary / diagnosis. Tuberculosis, Pulmonary / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15361216.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Melilli GA, Nappi L, Carriero C, Lapresa M, Loizzi V, Caradonna F, Quaranta M, Putignano G: Malignant mixed mullerian tumor of the ovary: report of four cases. Eur J Gynaecol Oncol; 2001;22(1):67-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed mullerian tumor of the ovary: report of four cases.
  • INTRODUCTION: Malignant mixed mullerian tumor (MMMT) of the ovary is an extremely rare gynaecologic neoplasm that represents 1% of the malignances of this organ.
  • Stage I disease is rare because it is asymptomatic in early stage.
  • CASE REPORTS: In the Department of Obstetrics and Gynecology of the University of Bari four cases of MMMT of the ovary were diagnosed.
  • Three patients were in stage IIIC and one of them was a homologous MMMT; the fourth patient was affected by a heterologous stage IV MMMT.
  • All women were treated with surgery and chemotherapy.
  • Two patients are alive 14 and 12 months after diagnosis.
  • CONCLUSIONS: The malignant mixed mullerian tumor (MMMT) of the ovary is a particularly aggressive tumor, especially in advanced stages.
  • The survival rate is very low in spite of surgery, chemotherapy and radiotherapy.
  • The optimal treatment for this neoplasm is unknown because of its rarity.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11321500.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Scholz HS, Benedicic C, Haas J, Tamussino K, Petru E: Stage IV ovarian cancer: prognostic factors and survival beyond 5 years. Anticancer Res; 2001 Sep-Oct;21(5):3729-32
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV ovarian cancer: prognostic factors and survival beyond 5 years.
  • BACKGROUND: Ovarian cancer continues to be the leading cause of death due to gynecologic malignancies and most patients still present with advanced disease.
  • In the present study we evaluated long-term survival and prognostic factors in patients with stage IV ovarian cancer.
  • PATIENTS AND METHODS: The charts of 62 consecutive women with FIGO stage IV epithelial ovarian cancer were reviewed.
  • RESULTS: Chemotherapy was the only factor associated with longer survival.
  • CONCLUSION: Survival seemed to correlate with the possibility of administering chemotherapy.
  • Patients with verified stage IV ovarian cancer, in whom due to the initial tumor load, operative extent and concomitant illness, the possibility of postoperative chemotherapy administration seems questionable, might be considered for primary chemotherapy followed by surgery.
  • [MeSH-major] Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11848553.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


16. Ben-Zvi N, Shani A, Ben-Baruch G, Agmon-Levin N, Sthoeger Z, Huszar M, Ben-Arie A, Dgani R: Dermatomyositis following the diagnosis of ovarian cancer. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1124-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatomyositis following the diagnosis of ovarian cancer.
  • We present a case history of a woman who developed dermatomyositis following the diagnosis of stage IV ovarian cancer.
  • Dermatomyositis is a rare paraneoplastic syndrome that usually precedes the diagnosis of ovarian cancer by several months or years.
  • Ours is the fifth reported case of dermatomyositis after an established diagnosis of ovarian cancer in the literature.
  • [MeSH-major] Dermatomyositis / etiology. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / pathology. Paraneoplastic Syndromes / etiology
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Disease Progression. Fatal Outcome. Female. Humans. Immunosuppressive Agents / therapeutic use. Neoadjuvant Therapy. Neoplasm Staging

  • Genetic Alliance. consumer health - Dermatomyositis.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343193.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Immunosuppressive Agents
  •  go-up   go-down


17. Ohta S, Yamakawa Y, Hasegawa T, Tateno M, Matsui K: [Advanced ovarian cancer with Sister Mary Joseph's nodule--a case report]. Gan To Kagaku Ryoho; 2007 Jan;34(1):117-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced ovarian cancer with Sister Mary Joseph's nodule--a case report].
  • A metastatic umbilical tumor,which we call Sister Mary Joseph's nodule (SMJN), is a sign of poor prognosis despite the primary site of malignant tumor.
  • We describe here a patient with an advanced ovarian cancer and SMJN.
  • A 51-year-old woman was referred to our department for evaluation of an umbilical tumor.
  • As a result of systemic examination, the patient was diagnosed as stage IV ovarian cancer and rapidly underwent an optimal operation.
  • Postoperatively, the chemotherapy for advanced ovarian tumors was begun (paclitaxel 180 mg/m(2) and carboplatin AUC 5, 10 courses every 3 weeks).
  • The patient is well without signs of tumor recurrence or metastasis 10 months after the operation.
  • Forty percent of all navel neoplasms are malignant tumors.
  • It is important to perform a pathological examination of a navel neoplasm or a systemic examination as fast as possible.
  • [MeSH-major] Abdominal Neoplasms / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / secondary. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery. Umbilicus
  • [MeSH-minor] Carboplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Middle Aged. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220685.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


18. Rzepka-Górska I, Chudecka-Glaz A, Kosmider M, Malecha J: GnRH analogues as an adjuvant therapy for ovarian cancer patients. Int J Gynaecol Obstet; 2003 May;81(2):199-205
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GnRH analogues as an adjuvant therapy for ovarian cancer patients.
  • OBJECTIVES: Lowering gonadotropin levels with gonadotropin-releasing hormone (GnRH) analogues in patients with ovarian cancer remains open to debate.
  • The aim of this study was to assess the results of treatment in stage III and stage IV ovarian cancer patients who had surgery supplemented with chemotherapy, radiotherapy, and GnRH analogues.
  • Gonadotropin levels were monitored during treatment.
  • METHODS: The study group comprised 69 patients aged 27-70 years, stratified according to the type of treatment.
  • RESULTS: Statistically significant differences were noted when chemotherapy was supplemented with GnRH analogues and/or radiotherapy.
  • Levels of FSH were significantly lower in patients surviving at least 5 years or in complete remission at the time of this study.
  • CONCLUSIONS: Combined therapy can produce favorable results in late-stage ovarian cancer, and GnRH analogues have an important role in treatment strategy.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Goserelin / therapeutic use. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follicle Stimulating Hormone / blood. Humans. Luteinizing Hormone / blood. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12706278.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0F65R8P09N / Goserelin; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


19. Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, Shiromizu K, Kuzuya K, Kamura T, Kikuchi Y, Kodama S, Yamamoto K, Sato S: Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol; 2001 Jun;81(3):398-403
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study.
  • OBJECTIVE: In the present study, we conducted a multicenter retrospective analysis to elucidate the prognostic factors of stage IV epithelial ovarian cancer.
  • METHODS: In November 1999, 24 Japanese institutions received questionnaires regarding stage IV epithelial ovarian cancer patients.
  • Eligibility criteria included all patients with stage IV epithelial ovarian cancer who were surgically confirmed and initially treated in each institution between January 1990 and December 1997.
  • Data were collected regarding age, performance status, tumor histologic subtype, site of metastasis, preoperative CA125, cytoreductive surgery, residual disease after cytoreductive surgery, and response to primary chemotherapy.
  • RESULTS: Two hundred twenty-five patients with stage IV ovarian cancer were identified.
  • The most common site of extraperitoneal disease was malignant pleural effusion (39.6%).
  • Most patients received platinum-based combination chemotherapy for primary chemotherapy.
  • CONCLUSION: Optimal surgical debulking, performance status, and histology appear to be important prognostic factors of survival in patients with stage IV epithelial ovarian cancer.
  • [MeSH-major] Ovarian Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11371128.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Aletti GD, Podratz KC, Cliby WA, Gostout BS: Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol Oncol; 2009 Jan;112(1):22-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.
  • OBJECTIVES: We aimed to define the site-specific patterns of treatment failure in stage IV ovarian cancer.
  • METHODS: Data from all consecutive Mayo Clinic patients with stage IV epithelial ovarian cancer, from 1994 through 2003, were collected and analyzed.
  • RESULTS: Review of our patient database identified 109 patients with stage IV ovarian cancer: mean age, 62 years (range, 36-83 years); 5-year overall survival, 15%.
  • Most patients (74%) had intraperitoneal disease at the time of relapse, 36% had pleural effusion, and 49% had extraperitoneal metastases.
  • At the time of death 75% had intraperitoneal localizations, 51% had pleural effusion, and 46% had extraperitoneal metastases.
  • Extrapleural disease at the time of diagnosis predicted extrapleural disease at relapse and at last follow-up.
  • Most patients classified as having stage IV disease by pleural cytology only, as opposed to all other patients, had intraperitoneal disease at relapse (88% vs 58.7%, P=.001) and last follow-up (88.5% vs 59.6%, P=.001).
  • Patients having stage IV disease by pleural cytology only had survival benefit when disease was optimally debulked in the abdomen and pelvis (median survival, 3.1 years vs 1.3 years; P=.001).
  • CONCLUSIONS: Clinical trials for stage IV ovarian cancer should reflect the site-specific risks for recurrence according to disease location at diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Retrospective Studies. Treatment Failure

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947860.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds
  •  go-up   go-down


21. Qian J, Shi Y, Chen X: [Clinical analysis of 25 cases of malignant transformation of endometriosis of the ovary]. Zhonghua Fu Chan Ke Za Zhi; 2000 Nov;35(11):667-9
MedlinePlus Health Information. consumer health - Ovarian Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 25 cases of malignant transformation of endometriosis of the ovary].
  • OBJECTIVE: To study clinicopathologic characteristics, treatment and prognostic factors of malignant transformation of endometriosis of the ovary.
  • METHODS: From 1981 to 1999, a total of 25 patients with malignant transformation of endometriosis of the ovary were retrospectively analyzed.
  • Histological type: of the 25 cases, 14 were endometrioid carcinomas, 2 were clear-cell carcinomas, 2 were adenoacanthoma, 1 was serous papillary adenocarcinomas, 6 were mixed epithelium tumor of ovary.
  • The exact area of histologic transition from benign to malignant epithelium was observed in 25 patients.
  • Stage: stage I 14, stage II 7, stage III 3, stage IV 1.
  • CONCLUSIONS: The exact incidence and prevalence of malignant transformation in endomertriosis is unknown.
  • Radical tumor resection combined with chemotherapy is the main therapeutic approach for malignant transformation of endometriosis of the ovary.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Endometriosis / pathology. Ovarian Diseases / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11218895.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Bristow RE: Surgical standards in the management of ovarian cancer. Curr Opin Oncol; 2000 Sep;12(5):474-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical standards in the management of ovarian cancer.
  • Surgery is the cornerstone of management of epithelial ovarian cancer and has broad applications throughout the clinical course of disease, from initial diagnosis to palliative care.
  • Comprehensive surgical staging is essential for precise prognostic determination and treatment planning for patients with apparent early-stage ovarian cancer.
  • With increasing radicality of cytoreductive surgical techniques and sophistication of postoperative care, it appears that an "optimal" surgical procedure is that which leaves the patient with no visible residual disease.
  • The survival benefits of cytoreductive surgery are also applicable to women with stage IV ovarian cancer, although the rate of success is somewhat attenuated compared with patients with stage III disease.
  • Recent data also indicate that with appropriate surgical selection criteria, secondary cytoreduction is associated with a significant prolongation of survival for patients with recurrent ovarian cancer.
  • Unfortunately, several recent publications illustrate how the decentralization of health care may have significant ramifications on the ability of women with known or suspected ovarian cancer to avail themselves of the surgical standard of care.
  • [MeSH-major] Ovarian Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Laparoscopy. Multivariate Analysis. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Postoperative Care. Survival Rate. Treatment Outcome. Uterine Neoplasms / pathology. Uterine Neoplasms / secondary. Uterine Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10975556.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 19
  •  go-up   go-down


23. Quero-Hernández A, Estrada-Correa R, Tenorio-Rodríguez H, Alvarez-Solís RM: [Malignant germ cell ovarian tumors: clinical characteristics, treatment and outcome]. Cir Cir; 2007 Mar-Apr;75(2):81-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant germ cell ovarian tumors: clinical characteristics, treatment and outcome].
  • [Transliterated title] Tumor de células germinales de ovario: características clínicas, y resultados del tratamiento.
  • BACKGROUND: Ovarian malignant neoplasms in young girls and teenagers are unusual.
  • The biological course of this heterogeneous group of neoplasm is unpredictable.
  • The main clinical symptom is chronic abdominal pain and palpable abdominal tumor.
  • Treatment has been improved with combined modality therapy.
  • We present treatment results of the germ cell subtype of malignant ovarian tumors.
  • METHODS: A retrospective review was performed from the medical records of 16 ovarian germ cell patients in order to analyze clinical characteristics, type of surgery performed and chemotherapy, as well as final treatment results.
  • RESULTS: Mean age was 13.8 years, and the left ovary was affected in 75% of cases.
  • Stage distribution was as follows: stage I, one patient diagnosed with choriocarcinoma; stage II, three cases (19%); stage III, 10 cases; and 2 cases in stage IV.
  • Mean number of chemotherapy cycles (cisplatin, etoposide and bleomycin) was 4, and 85% of patients survived >2 years.
  • CONCLUSIONS: Surgical procedure was conservative and a favorable outcome was observed for the chemotherapy cycles.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / epidemiology. Ovarian Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Cross-Sectional Studies. Female. Humans. Mexico / epidemiology. Ovariectomy. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511902.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


24. Billmire D, Vinocur C, Rescorla F, Cushing B, London W, Schlatter M, Davis M, Giller R, Lauer S, Olson T, Children's Oncology Group (COG): Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg; 2004 Mar;39(3):424-9; discussion 424-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study.
  • PURPOSE: The aim of this study was to perform an evaluation of outcome and the role of surgical staging components in malignant germ cell tumors (GCT) of the ovary in children and adolescents.
  • METHODS: From 1990 to 1996, 2 intergroup trials for malignant GCT were undertaken by Pediatric Oncology Group (POG) and Children's Cancer Study Group (CCG).
  • Stage I-II patients were treated with surgical resection and 4 cycles of standard dose cisplatin (100 mg/m2/cycle), etoposide, and bleomycin (PEB) chemotherapy.
  • Stage III-IV patients were treated with surgical resection and randomly assigned to chemotherapy with PEB or high-dose cisplatin (200 mg/m2/cycle) with etoposide and bleomycin (HDPEB).
  • Patients unresectable at diagnosis had second-look operation after 4 cycles of chemotherapy if residual tumor was seen on imaging studies.
  • An analysis of outcome data, operative notes, and pathology reports in girls with ovarian primary site was done for this report.
  • RESULTS: There were 131 patients with ovarian primary tumors of 515 entered on these studies.
  • Six-year survival rate was stage, I 95.1%; stage II, 93.8%; stage III, 98.3%; stage IV, 93.3%.
  • Surgical omissions resulting in protocol noncompliance resulted from failure to biopsy bilateral nodes (97%), no omentectomy (36%), no peritoneal cytology (21%), no contralateral ovary biopsy (59%).
  • More aggressive procedure than recommended by guidelines included total hysterectomy and bilateral salpingo-oophorectomy in 6 patients and retroperitoneal node dissection in 10 patients.
  • Correlation of gross operative findings with pathology results was carried out for ascites, lymph nodes, implants, omentum, and contralateral ovary.
  • CONCLUSIONS: Pediatric ovarian malignant GCT (stages I-IV) have excellent survival with conservative surgical resection and platinum-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Germinoma / pathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Female. Humans. Infant. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15017564.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


25. El-Lamie IK, Shehata NA, Abou-Loz SK, El-Lamie KI: Conservative surgical management of malignant ovarian germ cell tumors: the experience of the Gynecologic Oncology Unit at Ain Shams University. Eur J Gynaecol Oncol; 2000;21(6):605-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative surgical management of malignant ovarian germ cell tumors: the experience of the Gynecologic Oncology Unit at Ain Shams University.
  • PURPOSE: To evaluate the role of extended surgical staging in patients with malignant ovarian germ cell tumors in the presence of cisplatinum-based combination chemotherapy.
  • MATERIALS & METHODS: 16 patients aged between 13 and 40 years (mean 20.5) diagnosed and treated for malignant ovarian germ cell tumors at the Gynecologic Oncology Unit.
  • RESULTS: Six patients were diagnosed with dysgerminoma, six with immature teratoma and four with endodermal sinus tumor.
  • Only seven cases were primarily managed at the unit and were subjected to proper surgical staging as required by FIGO (two in each of the stages IC, IIC and IIIA and one in stage IV).
  • However, the remaining nine cases were referred to the unit, six after having unilateral salpingo-oophorectomy and no surgical staging, one patient after total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH+BSO), and one with recurrent dysgerminoma in the retroperitoneum and mediastinum following suboptimal treatment.
  • None of these cases were surgically re-explored and all including the first six cases were given the standard BEP chemotherapy for 4-6 courses (mean 5.8).
  • All patients are alive without any evidence of disease recurrence except for one patient with a stage IIIA immature teratoma who had a local and distant recurrence and is undergoing second-line chemotherapy.
  • CONCLUSION: In view of the high chemosensitivity and curability of ovarian germ cell tumors and their occurrence in young patients, every effort should be made to preserve one ovary and the uterus for future reproduction even in advanced cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Germinoma / surgery. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Egypt. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Neoplasm Staging. Reoperation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11214621.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


26. Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group: Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol; 2008 Jan 1;26(1):83-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
  • PURPOSE: To identify factors predictive of poor prognosis in a similarly treated population of women with stage IV epithelial ovarian cancer (EOC).
  • PATIENTS AND METHODS: A retrospective review of 360 patients with International Federation of Gynecology and Obstetrics stage IV EOC who underwent primary surgery followed by six cycles of intravenous platinum/paclitaxel was performed.
  • RESULTS: The median PFS and OS for this group of stage IV ovarian cancer patients was 12 and 29 months, respectively.
  • Multivariate regression analysis revealed that histology, malignant pleural effusion, intraparenchymal liver metastasis, and residual tumor size were significant prognostic variables.
  • Patients with less than 5.0 cm of disease initially and significant disease and/or comorbidities precluding microscopic cytoreduction may be considered for alternative therapeutic options other than primary cytoreduction.
  • [MeSH-major] Neoplasm, Residual / etiology. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cisplatin / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Female. Follow-Up Studies. Humans. Medical Records. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pleural Effusion, Malignant / etiology. Postoperative Complications / etiology. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Apr 1;26(10):1771-2; author reply 1772 [18375912.001]
  • (PMID = 18025437.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Nishio S, Ushijima K, Fukui A, Fujiyoshi N, Kawano K, Komai K, Ota S, Fujiyoshi K, Kamura T: Fertility-preserving treatment for patients with malignant germ cell tumors of the ovary. J Obstet Gynaecol Res; 2006 Aug;32(4):416-21
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-preserving treatment for patients with malignant germ cell tumors of the ovary.
  • AIM: The aim of this study was to investigate whether fertility preservation influences the clinical outcome in patients with malignant germ cell tumors of the ovary (MGCTO).
  • Thirty-five patients were included in the study, 14 with immature teratoma, 11 with dysgerminoma, eight with endodermal sinus tumor, and two with mixed germ cell tumor.
  • Twenty-three patients had International Federation of Gynecology and Obstetrics stage I (Ia, 11; Ib, 2; Ic, 10), one had stage II, seven had stage III, and four had stage IV disease.
  • RESULTS: Five patients with stage III or IV disease received radical surgery.
  • As the adjuvant treatment, 30 patients received chemotherapy, while five patients did not receive any chemotherapy.
  • She was 13 years old with a stage IV endodermal sinus tumor.
  • CONCLUSIONS: Irrespective of the stage of the disease, conservative surgery and adjuvant chemotherapy for MGCTO can achieve a favorable outcome in terms of survival and fertility.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery. Ovarian Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882268.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Sakuma M, Otsuki T, Yoshinaga K, Utsunomiya H, Nagase S, Takano T, Niikura H, Ito K, Otomo K, Tase T, Watanabe Y, Yaegashi N: Malignant transformation arising from mature cystic teratoma of the ovary: a retrospective study of 20 cases. Int J Gynecol Cancer; 2010 Jul;20(5):766-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation arising from mature cystic teratoma of the ovary: a retrospective study of 20 cases.
  • OBJECTIVES: Mature cystic teratoma (MCT) of the ovary rarely undergoes malignant transformation (MT).
  • Malignant transformation carries a significantly worse prognosis than epithelial ovarian cancer, regardless of whether postoperative chemotherapy or radiotherapy is applied.
  • The rarity of this tumor has posed a significant challenge to developing standardized postoperative management protocols.
  • The aim of this study was to review our experience with MT and to describe our current treatment practices.
  • The International Federation of Gynecology and Obstetrics stage distribution was as follows: 11 were stage I, 4 were stage II, 4 were stage III, and 1 was stage IV.
  • Eleven patients received adjuvant treatment: 8 were treated with chemotherapy, 2 with concurrent chemoradiation therapy, and 1 with radiation therapy.
  • Platinum-based chemotherapy was the first-line regimen.
  • Significant correlations between overall survival and age, stage, and residual tumor were presented (P = 0.044, P = 0.0107, P < 0.0001, respectively).
  • Eight patients with advanced stage died of their disease.
  • Four patients, however, were treated with adjuvant chemotherapy or concurrent chemoradiation therapy and survived more than 1 year.
  • One stage III patient had a disease-free interval of 2 years.
  • Two cases of SCC treated with combination platinum/taxane chemotherapy temporarily responded.
  • In the other 2 cases of SCC, concurrent chemoradiation therapy with nedaplatin also resulted in tumor regression.
  • CONCLUSIONS: The prognosis of MT is highly dependent on age, stage, and optimal cytoreduction.
  • Adjuvant treatment has not been standardized, although our experience supports the use of combination platinum/taxane chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cell Transformation, Neoplastic. Female. Humans. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973266.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


29. Markman M, Glass T, Smith HO, Hatch KD, Weiss GR, Taylor SA, Goodwin JW, Alberts DS: Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial. Gynecol Oncol; 2003 Mar;88(3):282-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial.
  • OBJECTIVE: To improve the survival of women with stage IV epithelial ovarian cancer the Southwest Oncology Group conducted a phase II trial examining two novel treatment strategies: (a) modification of the chemotherapy regimen (carboplatin/paclitaxel) based on evidence of response during treatment and (b) "maintenance therapy," with the monthly administration of single agent paclitaxel (maximum 2 years).
  • METHODS: Individuals with histologically documented stage IV ovarian, fallopian tube, or peritoneal cancers initially received a maximum of 3 courses of single agent carboplatin (AUC 6), with the decision to administer a subsequent course based on specific response criteria (i.e., declines in serum CA-125 or shrinkage of measurable mass lesions).
  • This was followed by single agent paclitaxel (150 mg/m(2)), delivered every 2 weeks for a maximum of 6 courses, again based on evidence of continued response to the treatment program.
  • The primary study end point was 2-year overall survival, which was to be compared to the survival of a previously published historical control population [stage IV ovarian cancer patients treated with a "standard" cisplatin/paclitaxel regimen (GOG 111; McGuire WP, N Eng E J Med 1996; 334:1)].
  • There were 2 treatment-related deaths.
  • There were no major treatment-related protocol violations.
  • CONCLUSIONS: While this trial demonstrated the feasibility of delivering a treatment regimen requiring frequent alternations in therapy based on predetermined changes in objective parameters of response, further exploration of this specific management approach does not appear warranted in stage IV ovarian cancer, based on the survival outcome compared to a reasonably similar historical control population.
  • As this trial demonstrates, the prospective determination of clinical end points in a phase II study (e.g., 2-year survival) that will lead to continued evaluation of a particular investigative strategy in a large-scale randomized trial can be an effective method to reduce the bias and uncertainty often associated with this complex decision process.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12648576.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA36850; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45461; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA46113; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA52386; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / CA58415; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA76132; United States / NCI NIH HHS / CA / CA76447
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


30. Bolis G, Scarfone G, Raspagliesi F, Mangili G, Danese S, Scollo P, Lo Russo D, Villa A, Aimone PD, Scambia G: Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. Eur J Cancer; 2010 Nov;46(16):2905-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study.
  • OBJECTIVE: The objective of this prospective randomized phase III trial was to compare paclitaxel plus carboplatin (PC) versus topotecan plus carboplatin and paclitaxel (TPC) in women with suboptimal stage III (residual tumour >1cm) or stage IV ovarian cancer to evaluate the survival rate and toxicities.
  • METHODS: Eligible for the study were patients aged at least 18 years old with histological/cytological diagnosis of FIGO stages III (residual tumour ≥1 cm after primary surgery)--IV epithelial ovarian cancer.
  • Patients were randomized to iv PC on day 1, every 21 days or iv topotecan daily for three days and PC on day 3, every 21 days.
  • The number of subjects with at least one event with possible relationship to study medication was 151 (88.8%) in the PC group and 139 (89.1%) in the TPC group (p=ns).
  • CONCLUSION: The results of the present study show that the addition of topotecan to a standard paclitaxel/carboplatin regimen in the treatment of advanced epithelial ovarian cancer did not result in significant advantages in terms of survival rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Topotecan / administration & dosage. Topotecan / adverse effects. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Ltd.
  • (PMID = 20673626.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


31. Sun T, Feng Y, Zhu Y, Zheng Y: Therapeutic strategy in the management of stage II-IV epithelial ovarian carcinoma. Chin Med J (Engl); 2000 Jul;113(7):625-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic strategy in the management of stage II-IV epithelial ovarian carcinoma.
  • OBJECTIVE: To investigate the optimal time of debulking in stage/II to stage IV epithelial ovarian carcinoma, considering corresponding advantages of both surgery and chemotherapy.
  • METHODS: From January 1989 to December 1996, ninety-five stage II to stage IV ovarian cancer patients were treated under two different regimens.
  • Group A-76 cases (2 cases in IIa stage, 4 cases in IIb stage, 6 cases in IIc stage, 58 cases in IIIc stage and 7 cases in IV stage) was managed according to a traditional surgery-chemotherapy regimen; and group B-19 cases (17 cases in IIIc stage and 2 cases in IV stage) was managed with a chemotherapy-surgery-chemotherapy regimen.
  • The average survival time of those with a residual focus > 2 cm was shorter than those with a residual focus < 2 cm, in both groups.
  • Sixteen out of the 51 patients with a residual focus > 2 cm had a second debulking operation, among whom 7 had preoperative chemotherapy.
  • In 9 cases without preoperative chemotherapy, the residuals were all > 2 cm.
  • The average survival time among these two groups were significantly different (P < 0.01). CONCLUSION:.
  • (1) For those patients in whom optimal debulking was clinically assessed to be possible, timely operation is mandatory. (2) For those inoperable advanced cases, chemotherapy-surgery-chemotherapy regimen is recommended. (3) For those with residuals > 2 cm and were assessed to be difficult to eradicate during second-look operation, multi-route chemotherapy (intro-arterial, intraperitoneal, and systematic) should be given before going on the second debulking operation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Neoplasm Staging. Prognosis. Reoperation. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11776033.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Lee KH, Lee IH, Kim BG, Nam JH, Kim WK, Kang SB, Ryu SY, Cho CH, Choi HS, Kim KT, Korean Gynecologic Oncology Group: Clinicopathologic characteristics of malignant germ cell tumors in the ovaries of Korean women: a Korean Gynecologic Oncology Group Study. Int J Gynecol Cancer; 2009 Jan;19(1):84-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics of malignant germ cell tumors in the ovaries of Korean women: a Korean Gynecologic Oncology Group Study.
  • We evaluated the clinicopathologic characteristics of malignant germ cell tumors in the ovaries of South Korean women and determined the prognostic factors affecting recurrence.
  • The distribution of the International Federation of Gynecology and Obstetrics stage was as follows: 128 cases (65.3%) in stage I, 27 cases (13.8%) in stage II, 39 cases (19.9%) in stage III, and 2 cases (1.0%) in stage IV.
  • Histologically, immature teratoma was the most common tumor type (n = 68), followed by dysgerminoma (n = 54), endodermal sinus tumor (n = 38), mixed form (n = 24), and choriocarcinoma (n = 12).
  • Postoperative chemotherapy was administered in 166 patients, and the most common regimen was bleomycin, etoposide, and cisplatin (n = 120).
  • Recurrence was observed in 13 patients (6.8%) and was influenced by the stage of the tumor and patient age (>40 years).
  • The results of this study demonstrate that most malignant germ cell tumors of the ovary in Korean women are detected in the early stage and have excellent survival outcomes with conservative operation and platinum-based chemotherapy.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Korea. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258947.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Lee JK; Park JJ; Cha MS; Kim JH; Lee JM; Park SY; Kim SC; Lee SK
  •  go-up   go-down


33. Suita S, Shono K, Tajiri T, Takamatsu T, Mizote H, Nagasaki A, Inomata Y, Hara T, Okamura J, Miyazaki S, Kawakami K, Eguchi H, Tsuneyoshi M, Committee for Pediatric Solid Malignant Tumors in the Kyushu Area: Malignant germ cell tumors: clinical characteristics, treatment, and outcome. A report from the study group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan. J Pediatr Surg; 2002 Dec;37(12):1703-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant germ cell tumors: clinical characteristics, treatment, and outcome. A report from the study group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan.
  • PURPOSE: This study aims to assess the prognostic factors and optimal treatments for malignant germ cell tumors (MGCT) in childhood.
  • The prognostic factors and treatments were assessed based on the 5-year survival rate. RESULTS:.
  • (1) Stage: 100% for stage I (n = 54), 75.0% for stage II (n = 4), 67.3% for stage III (n = 14), and 54.8% for stage IV (n = 33); Unknown: n = 12. (2) Primary site: 93.4% for the testis (n = 52), 86.7% for the ovary (n = 31), 56.9% for the sacrococcygeal (n = 21), and 60.6% for others (n = 12); unknown: n = 1. (3) Surgical intervention for primary tumor: 100% for stage I with a complete resection (n = 53), 78.4% for stage III, IV with a complete resection (n = 26), and 33.3% for stage III, IV with an incomplete resection (n = 21). (4) Type of chemotherapy for the stage III and IV: 83.9% for the PVB (cisplatin, vinblastin, bleomycin; n = 13), 66.7% for the VAC (vincristine, actinomycin D, cyclophosphamide; n = 6), and 47.1% for other regimens (n = 25).
  • CONCLUSIONS: An early stage, a diagnosis under 1 year of age and a primary site in the gonads were favorable prognosis factors, whereas histologic findings of choriocarcinoma and liver or lung metastasis were unfavorable.
  • Radical complete resection alone is a sufficient treatment for localized MGCT.
  • The PVB regimen is optimal chemotherapy for advanced MGCT; however, high-risk cases still may require more aggressive treatment.
  • [MeSH-major] Germinoma / diagnosis. Germinoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Neoplasm Staging. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / surgery. Prognosis. Retrospective Studies. Survival Rate. Testicular Neoplasms / diagnosis. Testicular Neoplasms / epidemiology. Testicular Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • [CommentIn] J Urol. 2003 Sep;170(3):1040 [12926414.001]
  • (PMID = 12483635.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y: Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol; 2007 Aug;12(4):256-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
  • BACKGROUND: Irinotecan hydrochloride, a topoisomerase I inhibitor, has been preliminarily recognized as an effective agent against clear cell carcinoma of the ovary (CCC), but there are few clinical data.
  • METHODS: One hundred and seventeen patients at International Federation of Gynecology and Obstetrics (FIGO) stages Ic (ascites/malignant washing) - IV were identified by scanning the medical records of ten Japanese hospitals.
  • RESULTS: There was no significant difference in median age, performance status, FIGO stage, rate of optimal cytoreduction, or follow-up period between the CPT-P and TC groups.
  • Multiple regression analysis revealed that only residual tumor was an independent prognostic factor for PFS (P < 0.01).
  • CONCLUSION: CPT-P showed a potential therapeutic effect, at least no less than that of TC therapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Ovarian Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):52-6 [16445610.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):723-8 [12079522.001]
  • [Cites] Cancer Lett. 1998 Jun 19;128(2):211-8 [9683285.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):735-40 [14675308.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6880-8 [16203778.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):197-203 [15262142.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2503-12 [14633622.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):412-7 [8774649.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):604-10 [1537625.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):893-7 [15894369.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):394-9 [12648592.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):285-91 [16516283.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2157-63 [8918409.001]
  • [Cites] Jpn J Clin Oncol. 1999 Sep;29(9):434-7 [10563197.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):327-31 [10671681.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):789-93 [8631015.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1138-50 [1904477.001]
  • [Cites] Jpn J Cancer Res. 1994 Sep;85(9):966-71 [7961127.001]
  • [Cites] Gynecol Oncol. 1993 May;49(2):250-4 [8504995.001]
  • (PMID = 17701003.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0H43101T0J / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


35. Li H, Hong W, Zhang R, Wu L, Liu L, Zhang W: Retrospective analysis of 67 consecutive cases of pure ovarian immature teratoma. Chin Med J (Engl); 2002 Oct;115(10):1496-500
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of 67 consecutive cases of pure ovarian immature teratoma.
  • OBJECTIVE: To investigate the development regularity, treatment methods and prognosis of ovary immature teratoma (POIT).
  • There were 31 patients with stage I, 4 with stage II, 2 with stage III and 1 with stage IV lesions.
  • Unilateral adnexectomy was performed for stage I lesions.
  • From the 1980s, this was followed by four-cycles of combination chemotherapy (VAC, PVB or BEP x 3 cycles) as post-operative adjuvant therapy.
  • Combined chemotherapy and multiple operations were performed for advanced and recurrent lesions.
  • Thirty-five patients who had early lesions (stage I and II) had a 5-year survival rate of 91.4% (32/35).
  • The chief prognostic factors for this disease are clinical stage, pathological grade and adequate treatment.
  • It is characterized by the fact that recurrent tumors may be converted back to mature ones as time goes on.
  • With chemotherapy, these is a good opportunity to rescue those patients with recurrent tumors.
  • At present, treatment of POIT gives the most satisfactory results among all malignant ovarian germ cell tumor types.
  • Tests of serum specific tumor markers (CA19-9, AFP, CA125, CEA) performed preoperatively or before chemotherapy and during follow-up have been found helpful in the evaluation of prognosis.
  • [MeSH-major] Ovarian Neoplasms / mortality. Teratoma / mortality
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Child, Preschool. Female. Humans. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12490095.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


36. De Backer A, Madern GC, Oosterhuis JW, Hakvoort-Cammel FG, Hazebroek FW: Ovarian germ cell tumors in children: a clinical study of 66 patients. Pediatr Blood Cancer; 2006 Apr;46(4):459-64
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian germ cell tumors in children: a clinical study of 66 patients.
  • BACKGROUND: Ovarian germ cell tumors are rare in childhood.
  • The aim of this study is to review clinical presentation, management, and outcome in a two-center series of girls with ovarian germ cell tumor.
  • PROCEDURE: The records of 66 patients (median age 9 years) with histologically proven ovarian germ cell tumor (either benign or malignant), treated over a 44-year-span, were reviewed.
  • Most patients (52) were stage I, 4 were stage II, 6 stage III, and 1, with liver metastases, stage IV.
  • Sixteen patients had an emergency operation for tumor torsion.
  • Unilateral salpingo-oophorectomy was the most frequently performed procedure (n = 46), and ovarian-sparing tumorectomy was performed in 9 patients (one bilaterally).
  • Surgical removal of the tumor with or without the ovary and/or adnex was the sole treatment in 55 patients, chemotherapy was administered in 10 and radiotherapy + chemotherapy in one.
  • Two patients, with malignant disease, died.
  • The 64 survivors are now between 8 months and 44 years after treatment.
  • CONCLUSIONS: With a recurrence rate of 4.5% and a mortality rate of 3%, this series confirms the excellent prognosis for girls with ovarian germ cell tumor (GCT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206211.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


37. Kikkawa F, Nawa A, Kajiyama H, Shibata K, Ino K, Nomura S: Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol Oncol; 2006 Oct;103(1):171-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and prognosis of mucinous tumors of the ovary.
  • OBJECTIVE: Ovarian mucinous tumors consist of benign, borderline, and carcinomatous tumor, but the clinical characteristics of these 3 types have not been investigated in detail.
  • In this study, we compared the clinical characteristics and prognosis among these 3 types of mucinous tumors.
  • METHODS: One hundred sixty-one patients with mucinous cystadenocarcinoma and 143 patients with mucinous borderline tumor were registered between 1986 and 2003.
  • All patients were reviewed by two pathologists, then the mixed type and cases showing other organized malignant tumors were excluded from this study.
  • Patients with mucinous carcinoma staged Ib or more were treated postoperatively with 6 cycles of platinum-based chemotherapy.
  • RESULTS: Mean patient ages were 43.9, 44.7, and 49.7 years in patients with benign, borderline, carcinomatous tumor, respectively.
  • The ratio of early stage (I, II) to advanced stage (III, IV) was significantly lower in carcinoma than in borderline tumor.
  • The levels of tumor markers tended to increase with the level of malignancy.
  • In borderline tumor, 5 patients died of disease, and all of these patients had stage III disease with residual tumor after the initial surgery.
  • Patients with borderline tumor showed significantly better prognosis than those with carcinoma; however, there were no significant differences in prognosis between borderline tumor and carcinoma in patients with stage III tumor or residual tumor.
  • CONCLUSIONS: In mucinous tumors, measurement of CA72-4 is recommended to distinguish malignant from benign tumors.
  • Even in borderline tumor, patients with residual tumor showed a poorer prognosis than carcinoma, suggesting that complete resection is necessary for a good prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546243.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


38. Lo Curto M, Lumia F, Alaggio R, Cecchetto G, Almasio P, Indolfi P, Siracusa F, Bagnulo S, De Bernardi B, De Laurentis T, Di Cataldo A, Tamaro P: Malignant germ cell tumors in childhood: results of the first Italian cooperative study "TCG 91". Med Pediatr Oncol; 2003 Nov;41(5):417-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant germ cell tumors in childhood: results of the first Italian cooperative study "TCG 91".
  • BACKGROUND AND AIMS: About 20% of patients with germ cell tumor (GCT) are still resistant to therapy.
  • The site of the primary tumor was gonadal in 59, extragonadal in 36.
  • The stage was I in 39; II in 5; IIIa (microscopic residue) in 7; IIIb (macroscopic residue) in 16; IIIc (unresectable) in 13; IV in 15.
  • The treatment was surgery alone in 31; surgery plus radiotherapy in 1; chemotherapy +/- surgery in 63.
  • Post-chemotherapy resection in 19 (10 complete, 9 partial).
  • The chemotherapy regimen was carboplatin 400 mg/m2/day on days 1, 2; etoposide 150 mg/m2/day on days 1, 2; ifosfamide 1,500 mg/m2/day on days 21, 22; dactinomycin 1.5 mg/m2/day on day 21; vincristine 1.5 mg/m2/day on day 21.
  • Three patients died because of toxicity and two non-responders (to primary chemotherapy), died of progression; among the remaining 90 patients 20 relapsed, 9 are in second remission, 2 are alive with disease, and 9 died of disease progression (one from progression and intracranial hemorrhage).
  • Survival according to: (a) site: testis: 100%; ovary: 88%; sacrococcyx: 69.6%; other sites: 33.3% (P < 0.001);.
  • (b) stage: I and II: 100%; IIIa: 83.3%; IIIb: 84.6%; IIIc: 60.6%; IV: 53.2% (P < 0.001);.
  • All the pts who had complete resection of the primary tumor at diagnosis or at delayed surgery, remained in remission.
  • CONCLUSIONS: Multivariate analysis showed that the primary site of tumor was the only independent prognostic factor for survival and EFS.
  • [MeSH-major] Germinoma / pathology. Germinoma / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Testicular Neoplasms / pathology. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Confidence Intervals. Female. Humans. Incidence. Italy / epidemiology. Male. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 14515380.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Terenziani M, D'Angelo P, Bisogno G, Boldrini R, Cecchetto G, Collini P, Conte M, De Laurentis T, Ilari I, Indolfi P, Inserra A, Piva L, Siracusa F, Spreafico F, Tamaro P, Lo Curto M: Teratoma with a malignant somatic component in pediatric patients: the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience. Pediatr Blood Cancer; 2010 Apr;54(4):532-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Teratoma with a malignant somatic component in pediatric patients: the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
  • BACKGROUND: Teratoma with a malignant somatic component (TMSC) is rare but described in adults, whereas information on pediatric presentation is sparse.
  • PROCEDURE: The Associazione Italiana Ematologia Oncologia Pediatrica identified 14 cases of TMSC.
  • RESULTS: The series (9 female, 5 male) showed the following disease: testis (2), sacrococcygeal (3), ovary (3), retroperitoneum (3), mediastinum (2), and foot soft tissue (1).
  • Distribution of the somatic component was: carcinoma (4), pancreatic neuroendocrine tumor (1), neuroblastoma (3), rhabdomyosarcoma (3), rhabdomyosarcoma plus liposarcoma, chondrosarcoma, neurogenic sarcoma (1), chondrosarcoma plus neuroectodermal sarcoma (1), malignant peripheral nerve sheath tumor (1).
  • Three patients were in stage I, four in stage II, three in stage III, and four in stage IV.
  • The pediatric disease appears to be more heterogeneous in tumor site distribution and MSC histology than in adults.
  • Chemotherapy optimized for histology should include reagents directed to the somatic malignancy, if chemosensitive.
  • Malignant GCT warrants GCT-directed chemotherapy.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Italy. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20049928.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
  • Nonsmall cell neuroendocrine carcinoma (NSCNEC) of the ovary is a rare and aggressive tumor commonly associated with other surface epithelial and germ cell neoplasms.
  • Anderson Cancer Center in a 16-year period (1990 to 2005).
  • In 8 cases, NSCNEC was associated with other epithelial neoplasms, including mucinous neoplasms of low malignant potential, mucinous carcinoma, endometrioid carcinoma, mixed endometrioid and mucinous carcinoma, and a high-grade carcinoma, not otherwise specified.
  • In 2 cases, the tumor was associated with a mature cystic teratoma; one of them also containing an invasive moderately differentiated adenocarcinoma.
  • A single case was associated with a benign ovarian cyst.
  • The latter case had a dermoid cyst in the contralateral ovary.
  • NSCNEC represented anywhere from 10% to 90% of the ovarian tumor.
  • According to the International Federation of Gynecology and Obstetrics staging system, 4 cases were stage I tumors, 3 cases were stage III tumors, and 4 cases were stage IV tumors.
  • Seven patients were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by chemotherapy.
  • One patient had a bilateral salpingo-oophorectomy with omentectomy and appendectomy followed by chemotherapy; 1 patient had a total abdominal hysterectomy with right salpingo-oophorectomy followed by chemotherapy; one had a bilateral salpingo-oophorectomy followed by chemotherapy, and one had a right salpingo-oophorectomy with appendectomy followed by chemotherapy.
  • Four of 5 patients who died of disease had either stage III or IV tumors and 3 of 5 patients who are alive without evidence of disease have stage I tumors.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Neuroendocrine / pathology. Immunoenzyme Techniques. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


41. Makhlouf AM, Fathalla MM, Zakhary MA, Makarem MH: Sulfatides in ovarian tumors: clinicopathological correlates. Int J Gynecol Cancer; 2004 Jan-Feb;14(1):89-93
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sulfatides in ovarian tumors: clinicopathological correlates.
  • OBJECTIVES: To investigate the expression of sulfatides in the tissue homogenates of malignant ovarian tumors, benign ovarian tumors, and control tissues and to study the relation between this marker and other clinico-pathological criteria such as the tumor type, grade of differentiation, surgical stage and ovulatory years.
  • SUBJECTS: Forty-six patients had malignant ovarian tumors.
  • Sixteen patients had benign ovarian neoplasm.
  • METHODS: A sample of the tumor or from the normal ovary (the control group) was sent for histopathological and biochemical examination.
  • In malignant tumors, the median value of sulfatides was significantly higher than in benign tumors [127 (71-193), P-value = 0.000].
  • Sulfatides were significantly higher in patients with more ovulatory years and tumors of advanced stages (stage III/IV) and poor differentiation.
  • CONCLUSIONS: Sulfatides may play a role in the pathogenesis of benign and malignant ovarian tumors.
  • It may also predict advanced stages in patients who are apparently early stage.
  • It is also a candidate to study of their association with response to chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Ovarian Neoplasms / metabolism. Sulfoglycosphingolipids / metabolism
  • [MeSH-minor] Adult. Carcinoma / metabolism. Case-Control Studies. Cross-Sectional Studies. Female. Germinoma / metabolism. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Ovarian Cysts / metabolism. Predictive Value of Tests. ROC Curve. Sex Cord-Gonadal Stromal Tumors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14764034.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Sulfoglycosphingolipids
  •  go-up   go-down


42. Yamashiro C, Yanagihara T, Hata T: Regression of liver metastases after high-dose chemotherapy and peripheral-blood progenitor-cell support in Stage IV ovarian cancer. Int J Gynaecol Obstet; 2000 Dec;71(3):245-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of liver metastases after high-dose chemotherapy and peripheral-blood progenitor-cell support in Stage IV ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma / drug therapy. Cystadenocarcinoma / secondary. Hematopoietic Stem Cell Transplantation. Liver Neoplasms / secondary. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Disease Progression. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11102614.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down






Advertisement